NCT06970847 2026-03-18
AMPLIFY
Clarity Pharmaceuticals Ltd
Phase 3 Recruiting
Clinical Trials
52 trialsNCT02064673 2026-03-17
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
University of Texas Southwestern Medical Center
Phase 3 Recruiting
NCT06056830 2026-03-16
CLARIFY
Clarity Pharmaceuticals Ltd
Phase 3 Recruiting
NCT06925737 2026-03-13
MK-2400-001
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06136650 2026-03-09
MK-5684-004
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06691984 2026-03-06
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
Amgen
Phase 3 Recruiting
NCT06551324 2026-03-04
MEVPRO-1
Pfizer
Phase 3 Recruiting
NCT06931340 2026-03-04
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT07028853 2026-03-04
MEVPRO-3
Pfizer
Phase 3 Recruiting
NCT04423211 2026-03-02
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Eastern Cooperative Oncology Group
Phase 3 Recruiting
NCT06855277 2026-02-24
AcTFirst
Novartis
Phase 3 Recruiting
NCT06235151 2026-02-17
Solar-Stage
Curium US LLC
Phase 3 Recruiting
NCT06439225 2026-02-11
OPTION-DDR
Canadian Cancer Trials Group
Phase 3 Recruiting
NCT06625034 2026-02-10
Radiation Therapy With RapidPlan Knowledge-based Planning vs Human-Driven Planning for Treatment of Prostate Cancer
Mayo Clinic
Phase 3 Recruiting
NCT06563388 2026-02-04
ID-COMET
Roswell Park Cancer Institute
Phase 3 Recruiting
NCT05946213 2026-02-02
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
NRG Oncology
Phase 3 Recruiting
NCT06764485 2026-01-28
rechARge
Celgene
Phase 3 Recruiting
NCT06470243 2026-01-22
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
SWOG Cancer Research Network
Phase 3 Recruiting
NCT06120491 2026-01-21
EvoPAR-PR01
AstraZeneca
Phase 3 Recruiting
NCT06205316 2026-01-20
SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
Mayo Clinic
Phase 3 Recruiting
NCT05838716 2026-01-15
ViPER
University of Rochester
Phase 3 Recruiting
NCT04134260 2026-01-14
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
NRG Oncology
Phase 3 Recruiting
NCT06592924 2026-01-14
TRIPLE-SWITCH
Canadian Cancer Trials Group
Phase 3 Recruiting
NCT06235697 2026-01-13
ASCENDE-SBRT
Canadian Cancer Trials Group
Phase 3 Recruiting
NCT07260435 2025-12-03
Apa/Enza-short
Erasmus Medical Center
Phase 3 Recruiting
NCT06274047 2025-10-30
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
M.D. Anderson Cancer Center
Phase 3 Recruiting
NCT05520255 2025-09-23
18F-PSMA-1007 PET/CT in Prostate Cancer - Access Trial 2022 to 2028
University of Alberta
Phase 3 Recruiting
NCT05974774 2025-09-19
Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Recruiting
NCT07052214 2025-09-10
BiPASS
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3 Recruiting
NCT01492972 2025-09-04
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
Proton Collaborative Group
Phase 3 Recruiting
NCT06986083 2025-08-05
A Study of Changes to Prostate Procedures
Memorial Sloan Kettering Cancer Center
Phase 3 Recruiting
NCT05448547 2025-07-01
GrandP/SPCG19
The Hospital of Vestfold
Phase 3 Recruiting
NCT03819101 2025-06-26
PEACE-4
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Recruiting
NCT03769766 2025-06-11
Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance
University of Texas Southwestern Medical Center
Phase 3 Recruiting
NCT04833426 2025-05-02
ENFORCE
Canisius-Wilhelmina Hospital
Phase 3 Recruiting
NCT06945315 2025-04-25
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
Icahn School of Medicine at Mount Sinai
Phase 3 Recruiting
NCT06112990 2025-04-16
CREATINE-52
University of Utah
Phase 3 Recruiting
NCT04794777 2025-03-20
Comparing "Salvage" Radiotherapy and Individualized PSMA PET/CT Targeted Treatment in With Relapsing Prostate Cancer
Karolinska University Hospital
Phase 3 Recruiting
NCT05169112 2025-03-20
Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy
Ottawa Hospital Research Institute
Phase 3 Recruiting
NCT06565247 2025-03-04
Evaluation of PSMA-PET and mpMRI in High-risk Prostate Cancer - Using Histopathologic Validation
Region Västerbotten
Phase 3 Recruiting
NCT06754085 2024-12-31
Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
HTA Co., Ltd.
Phase 3 Recruiting
NCT05613023 2024-09-19
PACE-NODES
Institute of Cancer Research, United Kingdom
Phase 3 Recruiting
NCT05352178 2024-07-03
SPARKLE
Universitaire Ziekenhuizen KU Leuven
Phase 3 Recruiting
NCT05847348 2024-07-03
68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3 Recruiting
NCT03594760 2024-06-04
PSMA-PET: Deep Radiomic Biomarkers of Progression and Response Prediction in Prostate Cancer
Centre hospitalier de l'Université de Montréal (CHUM)
Phase 3 Recruiting
NCT05799248 2024-05-24
Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management
MidLantic Urology
Phase 3 Recruiting
NCT06350825 2024-04-05
Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients
The First Affiliated Hospital with Nanjing Medical University
Phase 3 Recruiting
NCT05116475 2024-03-12
ALADDIN
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Phase 3 Recruiting
NCT04642027 2024-02-28
PERYTON
University Medical Center Groningen
Phase 3 Recruiting
NCT05781217 2023-11-18
URONCOR 06-24
Instituto de Investigación en OncologÃa Radioterápica - Fundación Española de OncologÃa Radioterápic
Phase 3 Recruiting